-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QJVoIYhtxxOq8FAyMn74kEVX6eLu9E17KGSoy6Aak/lL1SJJNGJsrJmTaBckjrpr
 +xAC0aoorWPLM6WULlGfpA==

<SEC-DOCUMENT>0001079973-04-000193.txt : 20040423
<SEC-HEADER>0001079973-04-000193.hdr.sgml : 20040423
<ACCEPTANCE-DATETIME>20040423105928
ACCESSION NUMBER:		0001079973-04-000193
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20040405
ITEM INFORMATION:		Other events
FILED AS OF DATE:		20040423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASPENBIO INC
		CENTRAL INDEX KEY:			0001167419
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				841553387
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50019
		FILM NUMBER:		04749691

	BUSINESS ADDRESS:	
		STREET 1:		1585 S. PERRY STREET
		STREET 2:		ASPENBIO INC.
		CITY:			CASTLE ROCK
		STATE:			CO
		ZIP:			80104
		BUSINESS PHONE:		(303) 794-2000

	MAIL ADDRESS:	
		STREET 1:		1585 S. PERRY STREET
		STREET 2:		ASPENBIO INC.
		CITY:			CASTLE ROCK
		STATE:			CO
		ZIP:			80104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aspenbio_8k042304.txt
<DESCRIPTION>CURRENT EVENT REPORT
<TEXT>
                     U.S. SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549



                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


         Date of report (Date of earliest event reported):    April 5, 2004
                                                            ---------------

                                 ASPENBIO, INC.
               --------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)


Commission file number: 0-50019
                        -------

         Colorado                                         84-1553387
- ----------------------------------          ------------------------------------
(State or other jurisdiction                (I.R.S. Employer Identification No.)
of incorporation or organization)


1585 S. Perry Street, Castle Rock, CO                                   80104
- ----------------------------------------                              ----------
(Address of principal executive offices)                              (Zip Code)


                                 (303) 794-2000
              -----------------------------------------------------
               Registrant's telephone number, including area code

<PAGE>

                                 AspenBio, Inc.

Information to be Included In the Report

Item 5.  Other Events and Regulation FD Disclosure.

Agreement with Officer and Director

     On April 5, 2004, the Company entered into a contingent agreement with
Roger Hurst, an officer, director and significant shareholder of the Company.
The agreement is contingent on the Company successfully raising a minimum of
$2,000,000 in equity funding by June 4, 2004 (the "Contingency"). If the
Contingency occurs, then the agreement provides that: (i) Mr. Hurst will
contribute back to the Company 1,896,757 shares of common stock owned by the him
at no cost, resulting in a substantial decrease in Mr. Hurst's ownership
position and the number of outstanding shares of the Company's common stock;(ii)
the Voting Agreement entered into with Mr. Hurst in June 2003 will terminate;
(iii) the terms of the outstanding promissory note issued by the Company to Mr.
Hurst in June 2003 (currently with a principal amount of approximately $960,000)
will be amended (the "Amended Note")to require payment of $200,000 immediately
after the Contingency, with the remaining indebtedness to be payable in minimum
monthly installments of $10,000 over the subsequent 36 months, with the entire
remaining principal and interest due and payable at the end of the 36 month
period; (iii) Mr. Hurst and the Company will enter into a written employment
agreement for a term extending at least one year beyond the later of: (A) the
date that the final payment is made under the Amended Note; or (B) the date Mr.
Hurst is either removed as a guarantor on all Company indebtedness, or the date
all indebtedness on which Mr. Hurst is a guarantor is repaid. In the event the
Contingency does not occur, all terms and conditions of the contingent agreement
will be null and void.

Status of Agreements with Certain Universities

The Company received notices from the University of Wyoming ("Wyoming") (dated
February 27, 2004) notifying the Company that its license agreement with Wyoming
will be terminated for late payment of fees and reimbursable expenses.
Subsequent agreements have been reached with the Wyoming granting the Company
extensions of the termination date until June 10, 2004.

The Company received notice of default and notice of termination letters (dated
March 1, 2004) from the Idaho Research Foundation, Inc.("IRF") with respect to
certain license agreements with IRF. A subsequent agreement has been reached
with the IRF retracting the previous termination letters and granting the
Company until June 18, 2004 to cure the financial defaults under the IRF license
agreements.


                                   SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.


                                                   AspenBio, Inc.
                                                   (Registrant)


Date: April 23, 2004                            /s/ Roger D. Hurst
      -------------                             ----------------------
                                                    Roger D. Hurst
                                                    President




<PAGE>


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
